Sabratek Corp. Infusion pumps

Sabratek Corp. 8/19/98 Infusion pumps

1. Failure to identify the actions needed to correct and prevent recurrence of non-conforming product. For example, it was determined that the _____ had a software problem which prevented the infusion rate from exceeding the bolus rate while operating in the “PCA” mode. While the software has been revised, the software development process was not reviewed to prevent this type of problem from recurring.

2. Failure to ensure that changes to specifications, processes or procedures are verified or where appropriate validated, before implementation. For example, there was no documentation of the verification or validation that the change to the software (referenced above) was effective. Also, there was no verification or validation that the addition of urethane coating to the CPU board was effective.

Need Your Input!

We have been researching where and when to hold our next 3-day 62304/FDA training course and we want your feedback!
1) Does the location in the US for a public course matter to you … for example, west coast (e.g., San Francisco area) vs. east coast (e.g., Boston)?
2) What locations do you prefer?
3) Would you prefer just the 3-day FDA/62034 course or to have the option of a full week 3-day course followed by cybersecurity 1-day, and a usability 1-day?
4) What other countries would you want to see our course offered publicly?
5) What are best two months of the year for the course?  What are the least favored (not workable) months?
Please respond by email to by Sep 25, 2019 if possible!

Corporate Office

15148 Springview St
Tampa, FL 33624
Partners located in the US (CA, FL, MA, MN) and Italy.